Keyword: Vertex Pharmaceuticals
Pooling their technologies, Editas will work on cancer treatments and BlueRock will focus on neurology, cardiology and immunology.
FDA chief Scott Gottlieb steps down; Gilead loses oncology leader; Deciphera CEO to retire; and DBV loses two executives ahead of peanut drug refile.
Merck licensed the drugs for $230 million upfront two years ago but has now granted Vertex the right to use them in certain gene-editing applications.
GSK chairman bows out; Editas CEO signs off; Roche dispatches exec to take over Genentech; and Vertex fires COO for code of conduct violation.
The clinical data team at Vertex asked themselves, how can we reduce our development timelines and costs—make things go faster, for less?
Symdeko doesn’t require specific blood-pressure monitoring, nor does it carry a warning about respiratory events, as Vertex's older treatment Orkambi does.
After a year's delay, Editas Medicine will start enrolling patients in a phase 1/2 trial of its CRISPR-based treatment for LCA10, a rare form of blindness.
The lack of efficacy seen in the phase 2b is another, potentially terminal, blow to the prospects of the Rho inhibitor.
The FDA lifted a clinical hold it placed on Vertex and CRISPR Therapeutics’ gene-edited stem cell therapy for sickle cell disease.
Inscripta aims to broaden access to CRISPR by offering new enzymes for free, and to boost R&D by outfitting scientists with a full suite of tools.